$103.40
-0.46-0.44%
At close: -
$103.50
0.10.10%
After Hours: 6:49 PM EDT
Comments
Loading...
Latest news for Novartis (NYSE:NVS) Stock
Novartis Stock (NYSE: NVS)
Categories: All
Tuesday, November 12, 2024
Wednesday, October 30, 2024
- Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
- Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
- USDA Says H5N1 Bird Flu Detected In Swine For...
- USDA To Begin Bulk Milk Testing For Bird Flu ...
- BMO Capital Maintains Market Perform on Novar...
Tuesday, October 29, 2024
- FDA Grants Accelerated Approval To Novartis's...
- US CDC Reports 36 H5 Bird Flu Cases In U.S. S...
- Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook
- Novartis shares are trading lower. The compan...
- Novartis 2024 Guidance Raised: Now Expects Ne...
- Novartis Q3 2024 Adj. EPS $2.06 Beats $1.96 E...
Monday, October 28, 2024
Thursday, October 24, 2024
Friday, October 18, 2024
Thursday, October 17, 2024
Wednesday, October 16, 2024
Monday, October 14, 2024
Friday, October 11, 2024
Thursday, October 10, 2024
Wednesday, October 02, 2024
Tuesday, October 01, 2024
Monday, September 30, 2024
Tuesday, September 24, 2024
Wednesday, September 18, 2024
- Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
- Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
- Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
- Novartis Announced New Data From ALITHIOS Ope...
- The FDA Approves Novartis' Kisqali (Ribocicli...